At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 1 enrolled

Drug / intervention

Coversindrug

Likely dose

Coversin 22.5mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03427060

NCT03427060Phase 2Completed

CONSENT II: Coversin in Paroxysmal Nocturnal Hemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms

AKARI Therapeutics·interventional·Posted Feb 9, 2018·Updated May 4, 2025

In Brief

A Phase 2 clinical trial evaluating Coversin for Paroxysmal Nocturnal Hemoglobinuria (PNH). Completed, enrolled 1 participant across 1 site.

Coversin in Paroxysmal Nocturnal Hemoglobinuria (PNH) in patients with resistance to Eculizumab due to complement C5 polymorphisms.

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

CountriesUnited States

Collaborators--

Phase 2CompletedFinished

201820192020202120222023202420252026

First PostedFeb 2018

Enrollment StartMay 2018

Primary CompletionNov 2018

Study CompletionFeb 2021

TodayJul 2026

First PostedFeb 9, 2018

Enrollment StartMay 14, 2018

Primary CompletionNov 15, 2018

Study CompletionFeb 3, 2021

TodayJul 2, 2026

Enrollment to primary: 6 monthsPosted 8.4 years ago

Coversindrug

Coversin - 22.5mg followed by 45mg for 6 months.